STAT3 and ovarian cancer: Mechanistic studies employed RNA interference, cholesterol modulation, lipid raft disruption with MβCD, cycloheximide chase assays, and STAT3 pathway inhibition.<h4>Results</h4>DHCR24 was consistently upregulated in chemoresistant ovarian cancer models and significantly correlated with poor patient survival.